Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 5/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 5/20 | 0.41 |
| ▸ | CBX7 | O95931 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063151 | 0.88 | SMO (0.59) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL1061180 | 0.86 | SMO (0.56) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL12962748 | 0.85 | SMO (0.39) | SMOSMN1; SMN2TP53POLBALDH1A1 | |
| SCHEMBL12962755 | 0.82 | SMO (0.52) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10314562 | 0.81 | SMO (0.48) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10314550 | 0.80 | SMO (0.49) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10314633 | 0.80 | SMO (0.49) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10314574 | 0.79 | SMO (0.48) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10314595 | 0.79 | SMO (0.48) | SMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL1062658 | 0.79 | SMO (0.68) | SMONPC1RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMO 1/4885SMN1; SMN2 3564/4885NPC1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.